BGNE

BeiGene, Ltd. (BGNE)

Last Price$226.70.0%
Market Cap$1,846.9M
LTM Total Debt to Total Equity
0.3x
5Y avg
0.2x
Biotechnology industry median
0.0x
Stock quality & Intrinsic value
5/10
11.4% undervalued

BeiGene, Ltd. Total Debt to Total Equity

Annual
Quarterly
LTM
Industry median
Company stand-alone
BGNE
Healthcare
Crunching data... Almost there!
Dec'13Dec'14Dec'15Dec'16Dec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23
Total Debt to Total Equity
(0.9x)
0.5x
0.0x
0.0x
0.2x
0.1x
0.3x
0.1x
0.1x
0.1x
0.3x
BGNE
Key metrics and insights to make informed decisions.
View full analysis
Overvalued or undervalued?
Check the intrinsic value for BGNE and see if it's the right time to invest.
Dive in

BeiGene, Ltd. (BGNE) Total Debt to Total Equity comparison analysis

Crunching data... Almost there!

BGNE key stats

USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Crunching data... Almost there!

Discover more Stock Ideas

FAQ

1) What is BeiGene, Ltd.'s Total Debt to Total Equity?

As of today, Microsoft Corp's last 12-month Total Debt to Total Equity is 0.3x, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Total Debt to Total Equity for BeiGene, Ltd. have been 0.2x over the past three years, and 0.2x over the past five years.

2) Is BeiGene, Ltd.'s Total Debt to Total Equity Good?

As of today, BeiGene, Ltd.'s Total Debt to Total Equity is 0.3x, which is higher than industry median of 0.0x. It indicates that BeiGene, Ltd.'s Total Debt to Total Equity is Bad.

3) How does BeiGene, Ltd.'s Total Debt to Total Equity compare to its peers?

As of today, BeiGene, Ltd.'s Total Debt to Total Equity is 0.3x, which is higher than peer median of 0.1x. The list of peers includes ALNY, NVO, VRTX, SMMT, UTHR, REGN, BNTX, INCY, RPRX, ARGX.